Physician profile
Ashley B Davis
NPI 1114960218
$3,335.14
in general payments reported to CMS, 2019-2025
38 companies · $321 in 2025
The $321 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $265 · 2021: $773 · 2022: $813 · 2023: $535 · 2024: $366 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $364.15 | 2019-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $353.00 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Abbvie INC. | $316.02 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $259.63 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Supernus Pharmaceuticals, INC. | $241.93 | 2021-2025 | Qelbree, Qelbree, Xyosted |
| Corium, LLC | $230.38 | 2022-2024 | Azstarys |
| Medtronic, INC. | $154.97 | 2022 | |
| Pfizer INC. | $145.75 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $122.39 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $118.07 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $77.78 | 2024-2025 | Airsupra |
| Sanofi Pasteur INC. | $75.38 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $72.77 | 2019-2021 | |
| Amgen INC. | $72.22 | 2020-2022 | |
| Tris Pharma INC | $62.46 | 2023-2025 | Dyanavel Xr |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $60.53 | 2024-2025 | Voquezna |
| Allergan, INC. | $57.93 | 2020 | |
| Antares Pharma, INC. | $54.77 | 2021-2023 | Nocdurna, Xyosted, Tlando |
| Dexcom, INC. | $44.64 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $39.17 | 2019-2021 | |
| Shire North American Group INC | $37.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.14 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.04 | 2019-2020 | |
| Kaleo, INC. | $31.39 | 2021 | |
| Exact Sciences Corporation | $30.96 | 2024 | Cologuard Collection Kit |
| Organon LLC | $28.53 | 2021-2023 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $27.47 | 2025 | |
| Lilly USA, LLC | $27.21 | 2021-2024 | Jardiance |
| Hikma Pharmaceuticals USA | $19.35 | 2021 | |
| Uswm, LLC | $19.00 | 2021 | |
| Seqirus USA INC | $18.22 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Halozyme INC | $17.76 | 2023 | |
| Collegium Pharmaceutical, INC. | $16.05 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $15.25 | 2020 | |
| Bausch Health US, LLC | $13.72 | 2021 | |
| Esperion Therapeutics, INC. | $13.59 | 2023 | Nexletol |
| Ironwood Pharmaceuticals, INC | $13.57 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.36 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.